Colorado could cap payments for Amgen’s Enbrel
Colorado could be the first state to bring action against a drug maker via a state prescription drug affordability board, over Amgen's drug Enbrel.
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
A litmus test for states’ drug pricing power
Colorado could soon cap how much the state will pay for Amgen’s autoimmune drug Enbrel — in what would be the first such move from a state prescription drug affordability board. Affordability boards have been around for years, but they’ve been slow to actually act on lowering costs for patients.
What's Your Reaction?
